Pharma industry concerns about NZ continue, after Wikileaks reveals 2004 tactics
This article was originally published in Scrip
Executive Summary
The R&D pharmaceutical industry has always had a rather shaky relationship with one of the world's toughest reimbursement bodies, namely the monopoly purchasing power held by New Zealand's pharmaceutical management agency, Pharmac. So it comes as no surprise to read – in a leaked US embassy cable on Wikileaks' website this week – of some of the tactics used by industry to improve access in this rather small market, in value terms.